Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 2022

View Archived Issues

"Trojan horse" approach redirects tetanus immune response to tumors

Researchers unveil novel markers of GABA catabolism pathway abnormalities

Roche patents compounds for Gram-negative bacterial infections

German researchers divulge nitric oxide production inhibitors

Medshine Discovery presents new antifungal compounds

Gasherbrum Bio identifies GLP-1 receptor agonists

Aubrak Therapeutics patents new PROTACs for cancer

Regulus miR-155 inhibitors studied to treat ALS

Chugai gains access to Halozyme's ENHANZE drug delivery technology

BiondVax collaborates with Max Planck and UMG for development of NanoAbs

Insilico Medicine and EQRx enter drug discovery and development collaboration

PPARgamma isoforms have specific and separable roles in gene regulation and metabolism

Predictive Oncology validates Discovery 21 results

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...